Art. -Nr.: HY-116624

MAZ51

8 Cited Publications

Kundenbewertung

Based on 8 publication(s) in Google Scholar

MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4) tyrosine kinase. MAZ51 inhibits VEGF-C-induced activation of VEGFR-3 without blocking VEGF-C-mediated stimulation of VEGFR2. MAZ51 had no effect on ligand-induced autophosphorylation of EGFR, IGF-1R and PDGFRβ. MAZ51 blocks proliferation and induces apoptosis in a wide variety of tumor cells. Antitumor activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.76%
CAS. Nr.: 163655-37-6
Formel: C₂₁H₁₈N₂O
Molecular Weight:314.38

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years

* The compound is unstable in solutions, freshly prepared is recommended.

MAZ51 Chemical Structure

CAS. Nr.: 163655-37-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (8)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

VEGFR3

Alle VEGFR Isoform-spezifische Produkte anzeigen :

In Vitro

MAZ51 (2.5-10 μM; 24 hours) blocks proliferation and induces apoptosis in a wide variety of tumor cells^[2].
MAZ51 (0.5-50 μM; 25 minutes) has no effect on ligand-induced autophosphorylation of EGFR, IGF-1R and PDGFRβ in A431 cells, HEK-293 cells, and PAE cells, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:

MT450, 1AS, ASM, G, AT6.1, MTLN3, MTLY, NM-081 cells
Concentration:

2.5, 10 μM
Incubation Time:

24 hours
Result:

Induced apoptosis in a wide variety of tumor cells.

Apoptosis Analysis^[2]

Cell Line:

MT450, 1AS, ASM, G, AT6.1, MTLN3, MTLY, NM-081 cells
Concentration:

2.5, 10 μM
Incubation Time:

24 hours
Result:

Blocked proliferation in a wide variety of tumor cells.

In Vivo

MAZ51 (8 mg/kg; i.p.; daily for 15 day) significantly suppresses the growth of MT450 tumors^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Wistar Furth rats (bearing MT450 cells)^[1]
Dosage:

8 mg/kg
Administration:

Intraperitoneal injection; daily for 15 day
Result:

Significantly suppressed the growth of MT450 tumors.

Chemical Information

CAS. Nr. 163655-37-6
Appearance Solid
Molecular Weight 314.38
Formel C₂₁H₁₈N₂O
Color Orange to red
SMILES

CN(C1=C2C=CC=CC2=C(C=C1)/C=C3C(NC4=C/3C=CC=C4)=O)C
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years

* The compound is unstable in solutions, freshly prepared is recommended.

Publications (8)

All In Vivo Efficacy StudyIn Vivo ImagingIFHistological Imaging/StainingELISA

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

A Novel Cranial Bone Transport Technique Repairs Skull Defect and Minimizes Brain Injury Outcome in Traumatic Brain Injury Rats. [Abstract]

2025 May 31:e04467. PMID: 40448603

MAZ51 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 May 31:e04467. [Abstract]

Representative Nissl staining and images of gross view of the TBI rats injected with MAZ51 (MAZ51 in dimethyl sulfoxide was dissolved in 20% SBE‐β‐CD and artificial CSF, then loaded into a capsule of the osmotic pump with a total volume of 100 µL, continuously intra‐cisterna magna infusion at 1 mg/kg of body weight for 30 days). Quantification of percentage of lesion size, calculated by ratio of the lesion area in ipsilateral brain to whole area of contralateral brain.

MAZ51 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 May 31:e04467. [Abstract]

MAZ51 in dimethyl sulfoxide was dissolved in 20% SBE‐β‐CD and artificial CSF, then loaded into a capsule of the osmotic pump with a total volume of 100 µL, continuously intra‐cisterna magna infusion at 1 mg/kg of body weight for 30 days. Representative images of perilesional cortex stained with GFAP (green) and Iba1 (red), scale bar = 50 µm.
J Nanobiotechnology

Exosomes derived from platelet-rich plasma alleviate synovial inflammation by enhancing synovial lymphatic function. [Abstract]

2025 Jul 16;23(1):522. PMID: 40671121

MAZ51 purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Jul 16;23(1):522. [Abstract]

MAZ51 (16 mg/kg; i.p.; every other day). Representative near-infrared (NIR) lymphatic imaging (ICG) of knee joints from each group and quantitative analysis of the lymphatic clearance rate (n = 5).

MAZ51 purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Jul 16;23(1):522. [Abstract]

MAZ51 (16 mg/kg; i.p.; every other day). Representative H&E-stained images of knee joint synovial tissue from each group with synovitis scores. Scale bars: 500 μm and 100 μm.

MAZ51 purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Jul 16;23(1):522. [Abstract]

MAZ51 (16 mg/kg; i.p.; every other day). Immunofluorescence staining of synovial tissue sections from each group, with F4/80 (green), Inos (red), and DAPI (blue). Scale bar: 20 μm.

MAZ51 purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Jul 16;23(1):522. [Abstract]

MAZ51 (16 mg/kg; i.p.; every other day). ELISA analysis of IL-1β and TNF-α levels in synovial tissue from each group. The results showed that significantly increased concentrations in PRP-Exos + MAZ51 group compared to the PRP-Exos + Vehicle group.
Alzheimers Dement

Cranial bone maneuver ameliorates Alzheimer's disease pathology via enhancing meningeal lymphatic drainage function. [Abstract]

2025 Jan 30:e14518. PMID: 39887820
J Ethnopharmacol

The regulation of lymphatic valve formation promotes lymphatic drainage to reduce atherosclerotic plaques: A novel mechanism of anti-atherosclerosis by Gualou-Xiebai. [Abstract]

2026 Feb 28:357:120937. PMID: 41270912
Exp Neurol

Peripheral nervous system lymphatic vessels: A simple delivery route to promote nerve regeneration. [Abstract]

2024 Jul:377:114783. PMID: 38688418
Mediators Inflamm

Tumor Necrosis Factor- α Promotes the Tumorigenesis, Lymphangiogenesis, and Lymphatic Metastasis in Cervical Cancer via Activating VEGFC-Mediated AKT and ERK Pathways. [Abstract]

2023 Apr 21:2023:5679966. PMID: 37124061
bioRxiv

2026 May 27.
Research Square Print

23 Dec 2022.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 8.33 mg/mL (26.50 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.1809 mL

15.9043 mL

31.8086 mL

5 mM

0.6362 mL

3.1809 mL

6.3617 mL

10 mM

0.3181 mL

1.5904 mL

3.1809 mL

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.83 mg/mL (2.64 mM); Clear solution

This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 4 mg/mL (12.72 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Kirkin V, et al. Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2. Eur J Biochem. 2001 Nov;268(21):5530-40. [Content Brief]

[2]. Kirkin V, et al. MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo. Int J Cancer. 2004 Dec 20;112(6):986-93. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.1809 mL	15.9043 mL	31.8086 mL	79.5216 mL
	5 mM	0.6362 mL	3.1809 mL	6.3617 mL	15.9043 mL
	10 mM	0.3181 mL	1.5904 mL	3.1809 mL	7.9522 mL
	15 mM	0.2121 mL	1.0603 mL	2.1206 mL	5.3014 mL
	20 mM	0.1590 mL	0.7952 mL	1.5904 mL	3.9761 mL
	25 mM	0.1272 mL	0.6362 mL	1.2723 mL	3.1809 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

MAZ51

Publications Citing Use of MedChemExpress (MCE) MAZ51

Alle VEGFR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (8)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

MAZ51 Related Classifications

HY-116624 Related Classifications